Table 3.
Results from linear mixed models comparing the difference in quality of life at the primary endpoint by treatment group and by treatment successa,b
A. Methotrexate (vs. Mycophenolate Mofetil) | B. Treatment Success (vs Treatment Failure) | |||||
---|---|---|---|---|---|---|
| ||||||
Coef. | 95% CI | P-value | Coef. | 95% CI | P-value | |
Vision-related QoL c | ||||||
NEI-VFQ | 2.2 | −1.4-5.8 | 0.23 | 9.8 | 6.2-13.5 | <0.001 |
IND-VFQ | 3.9 | −1.5-9.3 | 0.16 | 15.6 | 10.2-20.8 | <0.001 |
Health-related QoL d | ||||||
PCS | 0.6 | −1.3-2.6 | 0.51 | 3.6 | 1.6-5.5 | <0.001 |
MCS | −0.5 | −3.2-2.2 | 0.72 | 3.7 | 1.0-6.5 | <0.001 |
Primary endpoint was defined as 6 months from the baseline visit (or the time of treatment failure prior to 6 months)
All multivariable models controlled for baseline quality of life, age, sex, and site (random effect)
Vision-related quality of life scales: NEI-VFQ - National Eye Institute Visual Functioning Questionnaire; IND-VFQ - Indian Vision Function Questionnaire (Indian participants only)
Health-related quality of life scales: PCS - physical component score of the Medical Outcomes Study 36-Item Short Form Survey (PCS SF-36v2); MCS - mental component score of the Medical Outcomes Study 36-Item Short Form Survey (MCS SF-36v2)